Vaccination+
A watchlist for helminth vaccine development, immune-risk lessons and One Health deployment models.
Why helminth vaccines are hard
Vaccination against worms is scientifically plausible, but it is not a simple copy of viral or bacterial vaccine development. Many helminths are large, long-lived, multicellular parasites with several life stages, strong immune-modulating biology and repeated exposure in endemic communities. In places where prevalence is high, many people have already been infected before vaccination is considered.
That history matters. Some helminth vaccine attempts have failed or stalled because candidate antigens triggered strong pre-existing IgE responses in previously exposed people. The clearest warning example is the Na-ASP-2 hookworm vaccine, where development was halted after generalized urticaria in adults from a hookworm-endemic area. Future vaccines need endemic-population immunology, not just clean preclinical efficacy.
The malaria vaccines RTS,S and R21 are important because they show that vaccines against a complex eukaryotic parasite can be deployed in high-burden settings. But malaria is caused by Plasmodium, not a worm. Helminths present a different challenge: bigger organisms, chronic exposure, tissue migration, immune evasion and sometimes a goal that may be anti-fecundity or transmission reduction rather than sterilising immunity.
Where vaccination may fit best
- Human public health: vaccines may be most useful where they reduce intensity, anaemia, egg output, pathology or reinfection after deworming, even if they do not fully prevent infection.
- Rare or focal parasites: lower exposure settings may offer clearer prophylactic use cases, especially where drug options are thin or diagnosis comes late.
- Veterinary and One Health control: whole-herd or whole-flock vaccination can be realistic when animals are managed in defined populations and the benefit includes reduced transmission to humans.
- Combination control: vaccines may pair with drugs, sanitation, vector or intermediate-host control, surveillance and resistance-management strategies.
Current and notable vaccine initiatives
| Programme / antigen | Parasite and use case | Developers / organisations | Status and relevance | References |
|---|---|---|---|---|
| Na-GST-1 ± Na-APR-1 Human hookworm vaccine |
Necator americanus; prevention or reduction of hookworm burden, blood loss and anaemia. | Baylor / Texas Children’s Center for Vaccine Development, George Washington University, HookVac partners and endemic-site collaborators. | Clinical-stage vaccine family. Phase 1 trials in adults and children support safety/immunogenicity; a 2026 phase 2 controlled human infection study reported protective effects for Na-GST-1/Al-CpG. | Gabon adult Phase 1; Gabon child Phase 1; 2026 Phase 2 CHHI trial. |
| Na-ASP-2 Discontinued hookworm lesson |
N. americanus; larval antigen originally pursued as a hookworm vaccine. | Hookworm vaccine developers including GW / Sabin-associated programmes. | Important negative lesson. Development was halted after IgE-associated generalized urticaria in previously infected adults in Brazil, showing why endemic-population immune screening is central for helminth vaccines. | J Allergy Clin Immunol paper; Na-GST-1 safety paper discussion. |
| Sm-p80 / SchistoShield® | Schistosoma mansoni; prophylactic and anti-fecundity schistosomiasis vaccine concept. | PAI Life Sciences / Texas Tech-associated programme, with GMP manufacturing and technology-transfer partners. | First-in-human clinical development reported. The antigen is positioned for further schistosomiasis vaccine trials after GMP manufacture and Phase 1 safety/immunogenicity work. | GMP SchistoShield assessment; first-in-human Sm-p80 trial. |
| Sm14 / GLA-SE | Schistosoma mansoni and potential cross-fluke relevance; schistosomiasis vaccine candidate. | Fiocruz-led programme with international development partners. | Clinical-stage recombinant antigen programme. Especially relevant as a humanitarian vaccine model aimed at populations living in areas at risk of infection. | Phase Ib clinical trial paper. |
| Sm-TSP-2 | S. mansoni; schistosomiasis vaccine antigen based on a parasite tetraspanin. | Baylor / Texas Children’s, James Cook University and collaborating schistosomiasis vaccine researchers. | Important antigen-discovery and preclinical-development line. Useful as a target class for comparing tegument and surface-antigen vaccine approaches. | Sm-TSP-2 PLOS NTD paper. |
| Barbervax® / hidden gut antigens | Haemonchus contortus; sheep and goat barber’s pole worm. | Moredun Research Institute, Australian veterinary partners and commercial manufacturers. | Commercial veterinary success and a proof that nematode vaccination can work in managed herds/flocks. Also highlights manufacturing challenges because native antigen production depends on adult worms. | MLA Barbervax report; recombinant / glycoengineered follow-up. |
| EG95 hydatid vaccine | Echinococcus granulosus; sheep/goat vaccination to reduce cystic echinococcosis transmission to humans. | Lightowlers / Heath lineage and veterinary vaccine producers including Tecnovax. | Strong One Health example: vaccinating livestock can interrupt a zoonotic worm life cycle and protect human communities indirectly. | Australia/Argentina vaccine trials; Providean Hidatil EG95 product page; Morocco field evaluation. |
| TSOL18 / Cysvax™ | Taenia solium; pig vaccination to reduce porcine cysticercosis and human neurocysticercosis risk. | University of Melbourne / GALVmed-associated development and field partners. | Another One Health vaccine model: vaccinate the animal host, often alongside oxfendazole, to reduce human disease transmission. | TSOL18 vaccine development review; GALVmed market report. |
| Fasciola vaccine candidates | Fasciola hepatica; liver fluke in sheep/cattle, with human zoonotic relevance. | Academic veterinary-parasitology groups testing recombinant and multivalent antigen cocktails. | No broadly available commercial vaccine yet, but active candidate work is important because triclabendazole resistance and livestock burden keep pressure on new control tools. | multivalent sheep vaccine trial; protease / anti-protease vaccine strategy. |
What Helminthix would track
Vaccination+ is a landscape page, not a claim that vaccines are always the right answer. We would track antigen candidates, immune-risk data, adjuvant choices, endemic-population safety, animal-reservoir strategies, challenge models, manufacturing feasibility and how vaccines could combine with cheap drugs and surveillance.